Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: A double blind, randomised trial on structure modification

Annals of the Rheumatic Diseases

Volumn 71, Issue 6, 2012, Pages 891-898

  Verbruggen, Gust ^a   Wittoek, Ruth ^a   Vander Cruyssen, Bert ^a   Elewaut, Dirk ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANGINA PECTORIS; ARTICLE; BONE EROSION; BONE PLATE; CONJUNCTIVITIS; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; ERYTHEMA; FEMALE; FINGER JOINT; FINGER OSTEOARTHRITIS; FOLLICULITIS; FOLLOW UP; GHENT UNIVERSITY SCORE SYSTEM; HAND OSTEOARTHRITIS; HAND RADIOGRAPHY; HEARTBURN; HUMAN; HYPERTENSION; IMAGE ANALYSIS; INJECTION SITE REACTION; JOINT CAVITY; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; SHOULDER PAIN; SIDE EFFECT; SKIN TOXICITY; TENDINITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VERTIGO; WEIGHT GAIN; WEIGHT REDUCTION;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; EDEMA; FEMALE; FINGER JOINT; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; PLACEBOS; RISK FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860918903     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2011.149849     Document Type: Article

References (40)

1. Mannoni A, Briganti MP, Di Bari M, et al. Epidemiological profile of symptomatic osteoarthritis in older adults: a population based study in Dicomano, Italy. Ann Rheum Dis 2003;62:576-8. (Pubitemid 36606294)
2. Bagge E, Bjelle A, Valkenburg HA, et al. Prevalence of radiographic osteoarthritis in two elderly European populations. Rheumatol Int 1992;12:33-8.
3. Dillon CF, Hirsch R, Rasch EK, et al. Symptomatic hand osteoarthritis in the United States: prevalence and functional impairment estimates from the third U.S. National Health and Nutrition Examination Survey, 1991-1994. Am J Phys Med Rehabil 2007;86:12-21. (Pubitemid 46360559)
4. Stecher RM, Hauser H. Heberden's nodes; the roentgenological and clinical appearance of degenerative joint disease of the fingers. Am J Roentgenol Radium Ther 1948;59:326-37.
5. Crain DC. Interphalangeal osteoarthritis. JAMA 1961;175:1049-53.
6. Peter JB, Pearson CM, Marmor L. Erosive osteoarthritis of the hands. Arthritis Rheum 1966;9:365-88.
7. Verbruggen G, Veys EM. Numerical scoring systems for the anatomic evolution of osteoarthritis of the finger joints. Arthritis Rheum 1996;39:308-20. (Pubitemid 26065273)
8. Zhang Y, Niu J, Kelly-Hayes M, et al. Prevalence of symptomatic hand osteoarthritis and its impact on functional status among the elderly: the Framingham Study. Am J Epidemiol 2002;156:1021-7. (Pubitemid 35396931)
9. Dahaghin S, Bierma-Zeinstra SM, Ginai AZ, et al. Prevalence and pattern of radiographic hand osteoarthritis and association with pain and disability (the Rotterdam study). Ann Rheum Dis 2005;64:682-7. (Pubitemid 40559292)
10. Cavasin F, Punzi L, Ramonda R, et al. [Prevalence of erosive osteoarthritis of the hand in a population from Venetian area]. Reumatismo 2004;56:46-50.
11. Kwok WY, Kloppenburg M, Rosendaal FR, et al. Erosive hand osteoarthritis: its prevalence and clinical impact in the general population and symptomatic hand osteoarthritis. Ann Rheum Dis 2011;70:1238-42.
12. Haugen IK, Englund M, Aliabadi P, et al. Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingham Osteoarthritis Study. Ann Rheum Dis 2011;70:1581-6.
13. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000;191:275-86.
14. Komine M, Kukita A, Kukita T, et al. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. Bone 2001;28:474-83. (Pubitemid 32409998)
15. Wei S, Kitaura H, Zhou P, et al. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005;115:282-90. (Pubitemid 40385470)
16. Arora T, Padaki R, Liu L, et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine 2009;45:124-31.
17. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11. (Pubitemid 38608061)
18. Hoff M, Kvien TK, Kälvesten J, et al. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann Rheum Dis 2009;68:1171-6.
19. Møller Døhn U, Boonen A, Hetland ML, et al. Erosive progression is minimal, but erosion healing rare, in patients with rheumatoid arthritis treated with adalimumab. A 1 year investigator-initiated follow-up study using high-resolution computed tomography as the primary outcome measure. Ann Rheum Dis 2009;68:1585-90.
20. Altman R, Alarcón G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990;33:1601-10.
21. Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis Cartilage 1998;6 (Suppl A):37-8. (Pubitemid 28255103)
22. Verbruggen G, Goemaere S, Veys EM. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol 2002;21:231-43. (Pubitemid 34785013)
23. Verbruggen G, Wittoek R, Vander Cruyssen B, et al. Morbid anatomy of 'erosive osteoarthritis' of the interphalangeal finger joints: an optimised scoring system to monitor disease progression in affected joints. Ann Rheum Dis 2010;69:862-7.
24. Ravaud P, Giraudeau B, Auleley GR, et al. Assessing smallest detectable change over time in continuous structural outcome measures: application to radiological change in knee osteoarthritis. J Clin Epidemiol 1999;52:1225-30. (Pubitemid 29535423)
25. Wittoek R, Carron P, Verbruggen G. Structural and inflammatory sonographic findings in erosive and non-erosive osteoarthritis of the interphalangeal finger joints. Ann Rheum Dis 2010;69:2173-6.
26. Bellamy N, Campbell J, Haraoui B, et al. Dimensionality and clinical importance of pain and disability in hand osteoarthritis: development of the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index. Osteoarthritis Cartilage 2002;10:855-62. (Pubitemid 35378771)
27. Pattrick M, Aldridge S, Hamilton E, et al. A controlled study of hand function in nodal and erosive osteoarthritis. Ann Rheum Dis 1989;48:978-82. (Pubitemid 20014798)
28. Kjeken I, Dagfinrud H, Slatkowsky-Christensen B, et al. Activity limitations and participation restrictions in women with hand osteoarthritis: patients'descriptions and associations between dimensions of functioning. Ann Rheum Dis 2005;64:1633-8. (Pubitemid 41532049)
29. Jones G, Cooley HM, Bellamy N. A cross-sectional study of the association between Heberden's nodes, radiographic osteoarthritis of the hands, grip strength, disability and pain. Osteoarthritis Cartilage 2001;9:606-11. (Pubitemid 32998380)
30. Leeb BF, Sautner J, Andel I, et al. SACRAH: a score for assessment and quantification of chronic rheumatic affections of the hands. Rheumatology (Oxford) 2003;42:1173-8. (Pubitemid 37258479)
31. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986;322:547-9. (Pubitemid 16049204)
32. Polzer K, Schett G, Zwerina J. The lonely death: chondrocyte apoptosis in TNFinduced arthritis. Autoimmunity 2007;40:333-6. (Pubitemid 46845533)
33. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002;39:237-46. (Pubitemid 34626067)
34. Wang J, Verdonk P, Elewaut D, et al. Homeostasis of the extracellular matrix of normal and osteoarthritic human articular cartilage chondrocytes in vitro. Osteoarthritis Cartilage 2003;11:801-9. (Pubitemid 37407596)
35. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002;30:340-6. (Pubitemid 34154863)
36. Døhn UM, Skjødt H, Hetland ML, et al. No erosive progression revealed by MRI in rheumatoid arthritis patients treated with etanercept, even in patients with persistent MRI and clinical signs of joint inflammation. Clin Rheumatol 2007;26:1857-61. (Pubitemid 47520446)
37. Kirwan JR. The relationship between synovitis and erosions in rheumatoid arthritis. Br J Rheumatol 1997;36:225-8.
38. Magnano MD, Chakravarty EF, Broudy C, et al. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 2007;34:1323-7. (Pubitemid 46898115)
39. Fioravanti A, Fabbroni M, Cerase A, et al. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int 2009;29:961-5.
40. Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009;68:1863-9.